Proliferating Angioendotheliomatosis has historically been divided into two groups, (1) a reactive, involuting type and (2) a malignant, rapidly fatal type. : 598 The reactive involuting type, reactive Angioendotheliomatosis is an rare cutaneous condition characterized histologically by a dense proliferation of small capillaries, and occurs in people with various diseases including subacute bacterial endocarditis and end-stage atherosclerotic disease. These people present with various skin lesions and rashes - most commonly on the thighs. Treatment aimed at the underlying condition hastens the resolution of the lesions. The malignant type is an intravascular lymphoma, usually of the diffuse B-cell type, known as intravascular large B-cell lymphoma. It progresses rapidly through involvement of multiple body systems and mortality occurs in less than a year from the initial diagnosis. The average age of diagnosis being 55 years. The causative mechanism is unknown. In a few cases treatment with palliative chemotherapy has been effective. : 598

Classification of Proliferating Angioendotheliomatosis
Proliferating angioendotheliomatosis may be divided into two types:
a reactive type – Reactive angioendotheliomatosis
a malignant type – Intravascular large B-cell lymphoma

Treatment
In few cases palliative chemotherapy is effective. A 30-year-old woman was diagnosed with cutaneous proliferating angioendotheliomatosis. She was treated with a local excision and radiotherapy. See also
List of cutaneous conditions

References
External links


== External links ==
Neonatal hypoglycemia occurs when the neonates blood glucose level is less than the newborns body requirements for factors such as cellular energy and metabolism. There is inconsistency internationally for diagnostic thresholds. In the US, hypoglycemia is when the blood glucose level is below 30 mg/dL within the first 24 hours of life and below 45 mg/dL thereafter. In the UK, however, lower and more variable thresholds are used (<18 mg/dL at any time OR baby with abnormal clinical signs and a single value <45 mg/dL OR baby at risk of impaired metabolic adaptation but without abnormal clinical signs and a measurement <36 mg/dL and remaining <36 mg/dL at next measurement). The neonates gestational age, birth weight, metabolic needs, and wellness state of the newborn has a substantial impact on the neonates blood glucose level. There are known risk factors that can be both maternal and neonatal. This is a treatable condition. Its treatment depends on the cause of the hypoglycemia. Though it is treatable, it can be fatal if gone undetected. Hypoglycemia is the most common metabolic problem in newborns.Neonatal hypoglycemia occurs in between 1 in 3 births out of every 1,000 births but is hard to quantify internationally due to lack of consensus about diagnostic thresholds. It often occurs in premature babies, small full-term babies, babies of diabetic mothers, and is more common in neonatal hypoxic asphyxia, sclerosis, and infected sepsis. Severe hypoglycaemia with persistent or repeated episodes can cause damage to the central nervous system.